---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-038153"
form_type: "8-K"
ticker: "RKDA"
cik: "0001469443"
company_name: "Arcadia Biosciences, Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:03:09.691151+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Arcadia Q4 revenues up 57% to $1.2M; full-year net loss narrows to $14.0M

## Summary
- Q4 2023 product revenue $1.17M (+57% YoY); full-year revenue $5.33M (-28% from $7.42M due to prior-year grain sales and license revenue).
- Full-year net loss att. to common stockholders $13.98M ($11.30/share) vs $15.38M ($25.65/share) in 2022, improved by lower operating expenses.
- Cash, equivalents, and short-term investments totaled $11.6M at Dec. 31, 2023, down from $20.6M a year earlier; operating cash burn $15.3M.
- GoodWheat now in three categories (pasta, pancake/waffle mixes, mac & cheese) and >3,500 stores; Zola coconut water launched pineapple and lime flavors in Q1 2024.
- Company initiated strategic review in mid-2023 with Lake Street Capital Markets to explore M&A, sale, or other transactions to maximize GoodWheat value.

## SEC filing metadata
- accession: 0000950170-24-038153
- form_type: 8-K
- ticker: RKDA
- cik: 0001469443
- company_name: Arcadia Biosciences, Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1469443/000095017024038153/0000950170-24-038153-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1469443/000095017024038153/rkda-20240328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-038153
- JSON: https://secwatch.observer/filing/0000950170-24-038153.json
- Plain text: https://secwatch.observer/filing/0000950170-24-038153.txt

## Key facts
- Earnings Releases
  Arcadia Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.
  - Period: the fourth quarter and year ended December 31, 2023
  - Result: reported results
  source text: On March 28, 2024 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the fourth quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1469443/000095017024038153/0000950170-24-038153-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.